Glax­o­SmithK­line scraps a LAG3 study, mark­ing an­oth­er fail­ure for the pipeline af­ter a crit­i­cal set­back

An­oth­er gap has ap­peared in Glax­o­SmithK­line’s pipeline.

Fri­day morn­ing the Aus­tralian biotech Im­mutep put out word that Hal Bar­ron’s R&D group at GSK had de­cid­ed to scrap a Phase II proof-of-con­cept study in ul­cer­a­tive col­i­tis for their an­ti-LAG3 ther­a­py GSK2831781. Ac­cord­ing to the biotech, the pro­gram didn’t sur­vive an in­ter­im re­view.

The tri­al was stopped by GSK based on the as­sess­ment of clin­i­cal da­ta as part of a planned in­ter­im analy­sis con­duct­ed in con­sul­ta­tion with the tri­al’s Da­ta Re­view Com­mit­tee. GSK is con­duct­ing fur­ther re­port­ing, as­sess­ment and analy­ses of the ef­fi­ca­cy and safe­ty da­ta and eval­u­at­ing the bi­ol­o­gy to de­ter­mine next steps for the GSK2831781 de­vel­op­ment pro­gram.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA